BALCHEM CORP (BCPC) FY2025 10-K Annual Report
BALCHEM CORP (BCPC) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 20, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
BALCHEM CORP FY2025 10-K Analysis
Business Overview
- • Core business model: Specialty chemicals and ingredients for health, nutrition, and performance markets
- • 2026 emphasis on regulatory impact of EPA's EtO Interim Decision affecting sterilization products and applications
- • Strategic focus on stakeholder engagement to influence EPA risk assessments and regulatory compliance measures
- • Regulatory compliance costs expected to increase due to phased EtO use restrictions and monitoring requirements over next 10 years
- • Potential operational disruptions from future EtO emission controls pose business risk, reflecting heightened regulatory scrutiny
Management Discussion & Analysis
- • Revenue $1,037M, up 8.8% YoY; Human Nutrition & Health up $59.1M (9.9%), Animal Nutrition & Health up $16.1M (7.5%), Specialty Products up $8.2M (6.2%)
- • Operating margin 20.2% vs 19.2%, earnings from operations $209.3M, up 14.4%; net earnings $154.8M, up 20.5%
- • Best performing segment: Human Nutrition & Health earnings $153.9M, up 13.2%; worst: Animal Nutrition & Health earnings $18.7M, up 33.4% but lowest absolute profit
- • Cash flow from operations $216.6M, capex $43.5M with $40-45M planned for 2026; share repurchases $107.6M, dividends paid $28.3M in 2025
- • Management expects continued strong cash flow to fund growth and acquisitions; faces EU anti-dumping duties risk on choline chloride imports from China effective July 2025
Risk Factors
- • Regulatory/legal risk: Tariff and trade changes under the USMCA impacting exports and requiring compliance with evolving export duties and quotas
- • Geopolitical/macro risk: Supply chain disruption risk from Russia-Ukraine war and Middle East conflict causing material raw material access issues in Europe
- • Operational risk: Manufacturing facility risks include equipment failure, power outages, and compliance with environmental directives impacting profitability
- • Competition risk: Facing competition from larger firms with superior R&D and production resources affecting market share and product demand
- • Financial risk: Interest rate exposure from variable rates on five-year senior secured revolving credit agreement, including volatility in SOFR reference rates
BALCHEM CORP FY2025 Key Financial MetricsXBRL
Revenue
$1.0B
▲ +8.8% YoY
Net Income
$155M
▲ +20.5% YoY
Gross Margin
35.7%
▲ +48bp YoY
Operating Margin
20.2%
▲ +100bp YoY
Net Margin
14.9%
▲ +146bp YoY
ROE
12.3%
▲ +114bp YoY
Total Assets
$1.7B
▲ +7.0% YoY
EPS (Diluted)
$4.75
▲ +20.9% YoY
Operating Cash Flow
$217M
▲ +19.0% YoY
Source: XBRL data from BALCHEM CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on BALCHEM CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.